Shanghai Vitalgen Biopharma Co., Ltd.

This early-stage study tests a new gene therapy called VGN-R08b for people with Parkinson's disease who have a specific genetic change (GBA1 mutation). The treatment is given as an injection into the brain's fluid spaces. The main goals are to check safety and see if it can impro…